Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04615182 · ClinicalTrials.gov registry record · NA
Donor After Circulatory Death Heart CAP Trial
A NA study, sponsored by TransMedics.
- Completed
- Registry status
- NA
- Development phase
- 90
- Enrollment target
NCT04615182: Completed NA study, sponsored by TransMedics.
NCT04615182 is a NA study that has completed, run by TransMedics. The registered enrollment target is 90 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04615182, a NA study, has completed, sponsored by TransMedics.
- COMPLETED
- Registry status
- NA
- Development phase
- 90 participants
- Enrollment target
Study Summary
The Portable Organ Care System (OCS™) Heart for Resuscitating, Preserving and Assessing Hearts Donated after Circulatory Death Continued Access Protocol (OCS DCD Heart CAP)
Primary Outcome
Patient survival at 6 months post-transplant.
Interventions
- DEVICE Transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2020-11-25 |
| Est. Completion | 2022-06-29 |
| Phase | NA |
What the finished NCT04615182 record still lists
NCT04615182 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 1 intervention - of which Transplant is the first listed.
NCT04615182 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04615182 about?
NCT04615182 is a clinical study titled "Donor After Circulatory Death Heart CAP Trial". The Portable Organ Care System (OCS™) Heart for Resuscitating, Preserving and Assessing Hearts Donated after Circulatory Death Continued Access Protocol (OCS DCD Heart CAP)
What is the current status of trial NCT04615182?
This trial is currently completed. It is a NA study. The enrollment target is 90 participants. The study started on 2020-11-25. Estimated completion is 2022-06-29.
What interventions are being tested in trial NCT04615182?
The interventions under investigation include: Transplant (DEVICE).
Who is sponsoring clinical trial NCT04615182?
This trial is sponsored by TransMedics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04615182's enrollment target sits among peer trials
90 941st of 2000 higher than 1,029 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI